MarketPulse

10b5-1 plan

5 articles
The Motley FoolThe Motley Fool··Seena Hassouna

Establishment Labs Founder's $7.9M Stock Sale Masks Strong Q1 Earnings Beat

Establishment Labs founder's $7.9M stock sale on earnings day was pre-planned, not opportunistic. Q1 results reveal stronger story: 13.3% US revenue growth, third consecutive quarter of positive adjusted EBITDA, guidance raised.
ESTAearningsrevenue growth
The Motley FoolThe Motley Fool··Seena Hassouna

Travere Director Cashes In Near Peak, But $1.6M Stake Signals Conviction

Travere Therapeutics Director Roy Baynes sold 4,500 shares for ~$210K near 52-week highs but retained $1.6M stake, suggesting conviction despite partial exit.
TVTXinsider salestock options
The Motley FoolThe Motley Fool··Jonathan Ponciano

Arcutis Stock Surges 65% as Director Sells Shares Under Pre-Planned Trading Strategy

Arcutis director sells 10,000 shares via pre-planned trading arrangement as stock surges 65%. ZORYVE revenue hit $372.1M in 2025, up 123% YoY, with company achieving positive operating cash flow.
ARQTbiopharmaceuticalcommercialization
The Motley FoolThe Motley Fool··Jonathan Ponciano

Ligand CFO Cashes In on 80% Rally; Strong Fundamentals Support Gain

Ligand Pharmaceuticals CFO Octavio Espinoza sold $688K in stock under a prearranged plan. The sale reflects portfolio diversification, not concerns, as the biotech firm posts strong 2025 results.
LGNDbiotechearnings growth
The Motley FoolThe Motley Fool··Andy Gould

Delek Director Offloads $6.1M in Shares as Stock Surges 184% Year-Over-Year

Delek US Holdings director Ezra Uzi Yemin sold $6.1M in shares via pre-arranged plan, reducing holdings 14.9% despite company's strong operational turnaround.
DKXLEIEOfree cash flowprofit-taking